menu
    • menu
    [{"orgOrder":0,"company":"Ignota Labs","sponsor":"Montage Ventures","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2025","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Ignota Labs","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Ignota Labs \/ Montage Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Ignota Labs \/ Montage Ventures"},{"orgOrder":0,"company":"Ignota Labs","sponsor":"Kronos Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"2-(4-(Phenylsulfonyl)piperazin-1-yl)ethanol","moa":"CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ignota Labs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ignota Labs \/ Ignota Labs","highestDevelopmentStatusID":"7","companyTruncated":"Ignota Labs \/ Ignota Labs"}]

    Find Clinical Drug Pipeline Developments & Deals by Ignota Labs

    Menu

    Ignota Labs

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ignota Labs

                            United Kingdom arrow
                            CTAD25
                            Not Confirmed

                            Ignota Labs

                            United Kingdom arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 2-(4-(Phenylsulfonyl)piperazin-1-yl)ethanol

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Kronos Bio

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Ignota Labs Acquires Kronos’s Clinical Pipeline

                            Details : Under the acquisition of Istisociclib, the deal aims to advance CDK9-targeted therapy for ovarian neoplasms.

                            Product Name : KB-0742

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 06, 2025

                            Lead Product(s) : 2-(4-(Phenylsulfonyl)piperazin-1-yl)ethanol

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Kronos Bio

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ignota Labs

                            United Kingdom arrow
                            CTAD25
                            Not Confirmed

                            Ignota Labs

                            United Kingdom arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Preclinical

                            Sponsor : Montage Ventures

                            Deal Size : $6.9 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Ignota Labs Raises USD $6.9M Seed Funding to Turn Around Failed Drugs

                            Details : The funding will be used to expand the pipeline by acquiring additional distressed assets and for advancement into early-stage clinical trials of Ignota's first asset, a PDE9A inhibitor.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            February 26, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Montage Ventures

                            Deal Size : $6.9 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth